Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20547584 | 1.00 | CA1 (0.55) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL13465348 | 0.90 | SIRT5 (0.56) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL16909029 | 0.90 | SIRT5 (0.56) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL14378788 | 0.90 | CA1 (0.59) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL2600778 | 0.82 | SIRT5 (0.50) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL13827396 | 0.81 | CA1 (0.57) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL20067639 | 0.80 | CA1 (0.64) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL21012443 | 0.79 | L3MBTL1 (0.49) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL19546066 | 0.79 | MEN1 (0.54) | CA1CA2SIRT5HDAC4HDAC1 | |
| SCHEMBL1109105 | 0.79 | HDAC4 (0.45) | CA1CA2SIRT5HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070898-A1 | PROCESS FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | GLIOBLASTOMA FOUND INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20240352007-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL (CH) | 2024-10-24 | — | — | US | disclosed |
| EP-3615529-B1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BASILEA PHARMACEUTICA INT AG ALLSCHWIL (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-11891382-B2 | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof | Basilea Pharmaceutica International AG | 2024-02-06 | — | — | US | disclosed |
| CN-116947836-A | Method for preparing furazanobenzimidazole and crystal forms thereof | 巴斯利尔药物国际股份公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-110536890-B | Method for preparing furazanobenzimidazole and crystal forms thereof | 巴斯利尔药物国际股份公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20210115032-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3615529-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | Basilea Pharmaceutica International AG (CH) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018197475-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | Basilea Pharmaceutica International AG (CH) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115032-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | FANCI, CYP2F1, CYP4F3 | CA1 2657/4885CA2 1993/4885SIRT5 2556/4885 |
| US-11891382-B2 | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof | FANCI, CYP2F1, CYP4F3 | CA1 2657/4885CA2 1993/4885SIRT5 2556/4885 |
| US-20240352007-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | FANCI, FANCD2, CYP2F1 | CA1 3252/4885CA2 2045/4885SIRT5 2564/4885 |
| US-20260070898-A1 | PROCESS FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BRCA1, PRKDC, KIT | CA1 933/4885CA2 1027/4885SIRT5 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.